Y-Intercept (HK)’s AbCellera Biologics ABCL Stock Holding History

Y-Intercept (HK)’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$425K	Buy	+54,193	New	+$265K	0.01%	1360
2023 Q3	–	Sell	-106,606	Closed	-$689K	–	1003
2023 Q2	$689K	Buy	+106,606	New	+$728K	0.07%	429
2022 Q2	–	Sell	-46,355	Closed	-$452K	–	828
2022 Q1	$452K	Buy	+46,355	New	+$439K	0.1%	293

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Y-Intercept (HK)'s ABCL Position: Q2 2026 in Review

Y-Intercept (HK) opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 54,193 shares worth $425K. The stake represents 0.01% of the portfolio and ranks #1360 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in ABCL as recently as Q2 2023.

Y-Intercept (HK) first reported a position in ABCL in Q1 2022 and has held it in 3 quarters since. The position peaked at $689K in Q2 2023. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Y-Intercept (HK) held 54,193 shares of AbCellera Biologics worth $425K as of Q2 2026.
AbCellera Biologics was a new Y-Intercept (HK) position in Q2 2026.
AbCellera Biologics made up 0.01% of Y-Intercept (HK)'s portfolio in Q2 2026, its #1360 holding.
Y-Intercept (HK) first reported a position in AbCellera Biologics in Q1 2022 and has held it in 3 quarters since.
Y-Intercept (HK)'s AbCellera Biologics position peaked at $689K in Q2 2023.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.